5Z-7-oxozeaenol slows the progression of Nonalcoholic steatohepatitis by inhibiting the activation of the mitogen-activated protein kinase (MAPK) signaling pathway via suppressing TAK1 (94). Here, WNK2 is linked to metabolic dysfunction-associated steatohepatitis.